Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang
Published on March 4, 2026.
Moderna has agreed to pay up to $2.25 billion in a settlement over its COVID vaccine patent dispute. The settlement resolves all U.S. and international legal actions regarding the use of lipid nanoparticle (LNP) technology in its COID vaccine. The company will pay $950 million upfront in July 2026, with an additional $1.3 billion dependent on the outcome of a separate legal appeal. The payment is seen as a significant win for Moderna, as it now has certainty it is well funded through multiple late-stage oncology readouts expected in 2026. However, if necessary, it could reduce the company's cash reserves to as low as $3.2 by 2026 and potentially lead to uncertain litigation against Pfizer (Pfe.
Related Articles
Iran could disrupt the Strait of Hormuz with drones for months
Iran could disrupt commercial traffic in the Strait of Hormuz with drones and missiles, posing a risk to energy prices and potential supply shortages.
Whiskey maker Brown-Forman tops quarterly estimates on steady demand
Brown-Forman's quarterly profits rose 2% to $1.06 billion, driven by strong whiskey demand in emerging markets, despite ongoing US sales decline.
Oklahoma AG wins key ruling against State Farm in insurance lawsuit
An Oklahoma judge rejected State Farm's plea to dismiss a lawsuit alleging widespread fraud, allowing state Attorney General Gentner Drummond to take over.